Editorial
Copyright ©The Author(s) 2024.
World J Orthop. Oct 18, 2024; 15(10): 908-917
Published online Oct 18, 2024. doi: 10.5312/wjo.v15.i10.908
Table 1 Orthobiologic usage indications and the level of evidence supporting its usage
Indication
Orthobiologic product
Level of evidence
Ref.
Knee osteoarthritisPRP1[18-20]
BMAC1[21,22]
SVF/MFAT/AD-MSC1[23-25]
Allogeneic MSC1[26-28]
Cultured chondrocytes (ACI/MACI)1[29]
Avascular necrosis of femoral headBMAC1[30-32]
SVF/MFAT/AD-MSC4[33,34]
Cultured osteoblasts4[35-37]
Lateral epicondylitisPRP1[1,38]
BMAC1[39]
Achilles tendinopathyPRP1[40,41]
BMAC1[39]
Patellar tendinopathyPRP1[42,43]
BMAC1[39]
Adhesive capsulitisPRP1[44,45]
Plantar fasciitis PRP1[46,47]
SVF4[48]
Degenerative disc diseasePRP1[49,50]
BMAC1[51-53]
FracturePRP1[54-56]
BMAC1[57-59]
ACL augmentPRP1[60,61]
BMAC1[62]
Meniscus repairPRP1[63-65]
BMAC4[66,67]
MFAT1[68]
Rotator cuff repair augmentPRP1[69,70]
BMAC1[39,71,72]
Ankle sprainPRP1[73]
Acute muscle injuriesPRP1[74]
Ankle osteoarthritis PRP1[75,76]
Carpal tunnel syndrome PRP 1[77,78]